Navigation Links
New drug dramatically improves survival in Hodgkin lymphoma patients
Date:6/27/2012

in early stages. However, if initial treatment fails, the patient may require an autologous stem cell transplant. This procedure uses the patient's own stem cells to replace immune system cells that are destroyed by high-dose chemotherapy or radiation.

About 50 percent of patients who undergo autologus stem cell transplants relapse. Among patients who relapse, only 10 percent survive.

The Food and Drug Administration last year approved brentuximab vedotin for patients who have either failed an autologous stem cell transplant, are ineligible for a stem cell transplant or have failed two multi-drug chemotherapy regimens.

Brentuximab vedotin is an antibody attached to a powerful chemotherapy drug. The antibody acts like a homing signal, bringing the chemo drug to lymphoma cells. "Brentuximab represents a very interesting new concept in the fight against cancer," said oncologist Tulio Rodriguez, MD, who treats Salerno and is medical director of Loyola's Bone Marrow Transplantation Program. "It delivers powerful chemotherapy right where it needs to be -- into the cancer cell."

Cancer patients frequently are debilitated not only by their cancer, but also by chemotherapy treatments. Targeted drugs such as brentuximab can spare patients from the harmful effects of traditional chemotherapy, Rodriguez said.

The study found that side effects from brentuximab were generally mild. Only 9 percent of patients suffered severe peripheral neuropathy, 2 percent had extreme fatigue and 1 percent had severe diarrhea.

Salerno said the only significant side effect she experienced was mild neuropathy, which went away when the dose was lowered.

Salerno, 43, has been battling Hodgkin lymphoma for 10 years. Although she is not cured, she said, "I feel great and have a good quality of life."

Salerno, who lives in Lombard, said her treatments inspired her to start a business. She markets the Joey Pouch -- a small, soft pouch
'/>"/>

Contact: Jim Ritter
jritter@lumc.edu
708-216-2445
Loyola University Health System
Source:Eurekalert

0

GOOD

Page: 1 2 3

Related medicine news :

1. Lung nodule matching software dramatically increases radiologists efficiency
2. US Drug Watchdog Dramatically Increases Their Efforts To Get All Recalled DePuy ASR Hip Implant Recipients Identified To The Best Possible Attorneys Before Time Runs Out
3. Automated breast ultrasound dramatically reduces physician interpretation time
4. Saliva test could dramatically increase detection of oral cancer
5. Invasive heart test being dramatically overused, Stanford study shows
6. Experimental drug improves muscle strength among male cancer patients
7. New delivery method improves efficacy of 2 common Parkinsons disease medications
8. Sleep improves functioning in Parkinsons patients, but reasons remain elusive
9. PAP therapy improves depressive symptoms in all patients with sleep apnea
10. STeleR study: Telerehab improves functioning after stroke
11. Tiny implanted coil improves lung function in patients with severe emphysema
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... ANN ARBORA University of Michigan study challenges previous ... League Baseball. , The study, a collaboration between ... and Florida, looks deeper into the controversial argument ... more strikes for pitchers of the same race. ... claim, said Jason Winfree, associate professor of sport ...
(Date:5/22/2013)... WEDNESDAY, May 22 (HealthDay News) -- Over the next ... United States is expected to more than double, topping ... research. The main factor driving the increase: an ... (AHA) and the American Stroke Association, was published May ... will absolutely strain the health care system," Dr. Bruce ...
(Date:5/22/2013)... may be reaping enormous income for patients whose ... contracted in their intensive care units. , In ... American Journal of Medical Quality , the ... an avoidable central line-associated bloodstream infection (CLABSI) costs ... a similar infection-free patient. Moreover, hospitals earn nearly ...
(Date:5/22/2013)... Phelps Memorial Hospital Center in Sleepy ... Center for individuals who would like to be screened ... is the deadliest form of cancer for both men and ... from lung cancer than from breast, colon and prostate cancer ... survival rates. It is well established that routine mammography ...
(Date:5/22/2013)... (PRWEB) May 22, 2013 Hurricane preparation ... your home. That’s why Amica Insurance is ... for the upcoming hurricane season. , “An important part ... Bryan Cook, a senior assistant vice president at Amica ... is before the threat of a storm.” , Flood ...
Breaking Medicine News(10 mins):Health News:U-M study challenges notion that umpires call more strikes for pitchers of same race 2Health News:Cost of Treating Strokes in U.S. Could Soar to $180B Annually by 2030: Report 2Health News:Cost of Treating Strokes in U.S. Could Soar to $180B Annually by 2030: Report 3Health News:Hospitals profit when patients develop bloodstream infections 2Health News:Hospitals profit when patients develop bloodstream infections 3Health News:Hospitals profit when patients develop bloodstream infections 4Health News:Phelps Memorial Hospital Center Establishes The Westchester Lung Nodule Center To Diagnose And Administer Lung Cancer Care 2Health News:Phelps Memorial Hospital Center Establishes The Westchester Lung Nodule Center To Diagnose And Administer Lung Cancer Care 3Health News:Reviewing Insurance Policies: a Key Part of Hurricane Preparations 2
... Executives, Pricing Analysts, and IP Professionals Meet on Expanding their ... Cambridge, MA. , ... Needham, MA ... division of Cambridge Healthtech Institute, recently posted details for its ...
... will donate $5 from the sale of its new Believe ... "The Mammography Fund is a great service to the community. ... Andrews, CEO of Founders Club, said.The Believe set retails for ... and specialty golf retail stores across the United States."St. Joseph,s/Candler ...
... clinical evaluationGRAND RAPIDS, Mich., Feb. 13 Sentinel Group ... Full Sense(TM) Device. The study was conducted at ... Baker MD, James Foote MD and Mexican doctor Jorge ... have the devices implanted for 6 weeks to evaluate ...
... KONG, Feb. 13 /PRNewswire-Asia-FirstCall/ -- China,s leading,integrated medical ... ("Golden Meditech" or "the Group"; HKEx: 8180) is ... financial year 2008/09 for the,period ended December 31, ... businesses, an increase of 25% on a year-on-year ...
... Haemacure Corporation (TSX:HAE) announces that it has implemented cost-cutting ... time, the Company will continue to seek financing and ... sale or merger of the Company. , Haemacure has ... Several parties have expressed interest in an equity financing; ...
... adult stem cell development, today announces that it has appointed Riccardo ... of Stemedica International, CH. Dr. Nisato will be responsible for ... Lausanne, Switzerland. , ... San Diego, Calif. (PRWEB) February ...
Cached Medicine News:Health News:Combination Products Executive Forum to be Hosted by CHI's Pharmaceutical Strategy Series 2Health News:Combination Products Executive Forum to be Hosted by CHI's Pharmaceutical Strategy Series 3Health News:Founders Club Proudly Supports the St. Joseph's/Candler Mammography Fund 2Health News:Weight Loss Without Hunger! 2Health News:Golden Meditech Releases FY2008/09 Q3 Results 2Health News:Golden Meditech Releases FY2008/09 Q3 Results 3Health News:Haemacure Restructures - Seeks Financing or Sale of the Company 2Health News:Haemacure Restructures - Seeks Financing or Sale of the Company 3Health News:Stemedica Announces the Appointment of Riccardo Nisato, MBA, PhD as Director of Manufacturing and Clinical Business Development for Stemedica International 2Health News:Stemedica Announces the Appointment of Riccardo Nisato, MBA, PhD as Director of Manufacturing and Clinical Business Development for Stemedica International 3
(Date:5/22/2013)... 22, 2013  The Leukemia & Lymphoma Society (LLS) ... Biotherapeutics, LLC, a joint venture between ImmunGene and Caliber, ... a Phase I clinical trial for a novel fusion ... many patients with indolent lymphomas who do not respond ... protein, IGN002, is a new class of biotherapeutics produced ...
(Date:5/22/2013)... , May 22, 2013 The new ... safe as the previous version used prior to 2010, ... Kaiser Permanente study published today in Vaccine. ... use beginning in 2010 after a series of trials. ... broader range of pneumococcal types than the previously used ...
(Date:5/22/2013)... 22, 2013 Pomerantz Grossman Hufford ... on behalf of investors of Intuitive Surgical, Inc. ("Intuitive ... (CUSIP: 46120E602) who purchased Intuitive Surgical common stock between ... Period"). Such investors are advised to contact ... or 888-476-6529, ext. 237. The investigation concerns ...
Breaking Medicine Technology:The Leukemia & Lymphoma Society, Valor Biotherapeutics and ImmunGene Create Partnership to Advance Novel Therapy for Non-Hodgkin Lymphoma Patients 2The Leukemia & Lymphoma Society, Valor Biotherapeutics and ImmunGene Create Partnership to Advance Novel Therapy for Non-Hodgkin Lymphoma Patients 3The Leukemia & Lymphoma Society, Valor Biotherapeutics and ImmunGene Create Partnership to Advance Novel Therapy for Non-Hodgkin Lymphoma Patients 4Kaiser Permanente Study Finds New Pneumococcal Vaccine Appears to be as Safe as Previously Used Vaccine 2Kaiser Permanente Study Finds New Pneumococcal Vaccine Appears to be as Safe as Previously Used Vaccine 3Kaiser Permanente Study Finds New Pneumococcal Vaccine Appears to be as Safe as Previously Used Vaccine 4SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Intuitive Surgical, Inc. - ISRG 2
... Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX ) today announced that results ... Solution, a prescription laxative packaged as a crystalline powder, will be presented ...   , , , ... of the study, entitled " An open-label, multi-center, randomized, 7-day crossover study ...
... Biosciences, Inc. (Nasdaq: NBIX ) announced today that Kevin Gorman , ... Deutsche Bank 35th Annual Health Care Conference in Boston . , ... The live presentation takes place Monday, ... 7:00 a.m. Pacific Time .  The presentation will be simultaneously webcast and may ...
Cached Medicine Technology:Kristalose(R) Clinical Data to Be Presented at Digestive Disease Week(R) Meeting 2Kristalose(R) Clinical Data to Be Presented at Digestive Disease Week(R) Meeting 3Neurocrine Biosciences to Present at the Deutsche Bank 35th Annual Health Care Conference 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: